Objective: Pulmonary arterial hypertension (PAH) is a serious disease characterized by progressive elevation of pulmonary arterial resistance, leading to right ventricular failure and death. We aimed to evaluate the effect of rapamycin (RAPA), a potent cell-cycle inhibitor, on exercise capacity, right ventricular hypertrophy, and pulmonary vascular remodeling.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a severe disease characterized by an increase in progressive pulmonary arterial resistance, which may cause right ventricle cardiac insufficiency, and death (1) . Although the reasons for PAH are complex, vasoconstriction originating from vascular endothelial damage in pulmonary arterioles, smooth muscle cell proliferation and hypertrophy, and constriction and remodeling of arterioles seem to be primary factors (2) .
Current treatments aim at restoring the balance between vasoconstriction and vasodilatation to prevent proliferation of endothelial and pulmonary artery smooth muscle cells (3) (4) (5) .
However, despite these treatments, the disease is still not curable.
Inflammation in the vascular wall, proliferation of endothelial cells and vascular smooth muscle, and vascular thrombosis are histopathological hallmarks of PAH (6) . Therefore, signaling pathways involved in proliferation should be targeted as part of a novel treatment strategy.
Imatinib was found to have anti-proliferative properties, and reversed the effect of PAH. A randomized, double-blind, placebo-controlled study showed that that imatinib influenced exercise capacity and hemodynamics (7, 8) . The positive effects of fasudil (a Rho kinase inhibitor) on altering vasoconstriction and pulmonary cell proliferation (9) afforded acute hemodynamic benefits in patients with PAH (10). Rosiglitazone is an effective antiproliferative agent and is a peroxisome proliferator activated receptor agonist. It has been reported to improve right ventricular hypertrophy and vascular remodeling in mice with hypoxia-induced PAH (11) .
The mammalian target of rapamycin (mTOR) protein, which functions in the Akt pathway, is one of the molecular targets of anti-proliferative treatments. It also has an important role in controlling cell growth, proliferation, survival, and is regulated by mitogenic and nutrient signals (12, 13) . Rapamycin (RAPA) is a bacterial macrolide isolated from Streptomyces hygroscopicus (14) and is an mTOR inhibitor. Blockage of mTOR by RAPA inhibits proliferation in numerous cell lines, including cancer cells, coronary arterial smooth muscle cells, vascular progenitor cells, and embryonic stem cells (15) (16) (17) (18) .
We aimed to evaluate the effects of RAPA on PAH induced by monocrotalin in terms of its effects on exercise capacity, right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vascular remodeling, and mortality.
METHODS

Study design and animals
Thirty-nine nine-week-old male Wistar-Albino rats (160-240 g) were used. All rats were provided by Kocaeli University Animal Reproduction Center and housed in the Animal Laboratory of Kocaeli University. Animals were caged in a controlled climate environment, with 12-hour light/dark cycles. Standard rat feed and water were provided ad libitum. All rats were allowed two weeks of acclimation to this environment before the experiment. The Kocaeli University Committee on the Use and Care of Animals approved the experiments and all investigations complied with the 1996 National Academy of Science Guide to the Care and Use of Laboratory Animals.
Rats were randomly assigned to one of the following groups: untreated animals (controls, n=10), monocrotaline group only (PAH control, n=15), and monocrotaline plus RAPA group (PAH-RAPA, n=14). In PAH control group, monocrotaline [Sigma-Aldrich, USA] 60 mg/kg was administered intraperitoneally on day 1 of the study period. In PAH-RAPA group, monocrotaline 60 mg/kg was administered intraperitoneally on day 1 of the study period, and
The Effect of Rapamycin in Pulmonary Hypertension RAPA (Wyeth Pharmaceuticals Inc., USA) 3 mg/kg was administered daily by orally from day 21 until the end of the study period.
Rats were monitored daily and mortality was recorded. After five weeks of monocrotaline application, all animals were subjected to an exercise test. Then, right ventricular pressure was measured under anesthesia. Heart and lungs were excised for histopathological investigation.
Exercise capacity
Exercise capacity was assessed by the modified forced-swimming test (19) . The animals were put in a cylinder tank (height, 50 cm; diameter, 30 cm) filled with water (25°C). The swimming time was defined as the total time from immersion, from which floating time was subtracted.
Right ventricular pressure
All rats were anesthetized by intraperitoneal application of 80 mg/kg ketamine hydrochloric acid (Ketalar; Eczacibasi Warner-Lambert Ilac Sanayi, Turkey) and 10 mg/kg xylazine hydrochloric acid (Rompun, Bayer, Turkey). Following intubation of the trachea, the animals were ventilated using a rodent ventilator (model 7025 Ugo Basile, Comerio, Italy.) Openchest measurements were conducted. To measure pulmonary arterial resistance, the chest of the rat was opened through a midline incision. An 18-gauge catheter filled with heparinized saline was inserted into the wall of the right ventricle and advanced into the pulmonary artery. Pressure recordings were performed using the MP 100A BIOPAC system (Santa Barbara, California).
Histology
Histological examination was performed by histopathologists blinded to study groups. After measurement of the right heart resistance, the heart and lungs of the decapitated animals were excised and fixed using neutral-buffered formalin (10%).
The heart, after central transverse sectioning, was stored in paraffin and 2-μm-thick sections were made and stained with hematoxylin-eosin. Right ventricular hypertrophy was expressed as the ratio of right ventricular wall area to (left ventricular wall area+interventricular septum)2 (RV/[LV+S]2).
After sectioning into 2-mm-thick samples, the lungs were placed in paraffin and 2-μm-thick sections were generated. Lung parenchyma incisions were dyed with hematoxylin-eosin, and immunohistochemically stained for α-smooth muscle actin (1:100, Dako, Glostrup, Denmark). Analysis of pulmonary vascular remodeling was performed as follows: For each animal, 20 pulmonary arteries with an external diameter of 50-200 μm were selected randomly. External diameter and medial muscular tissue thickness were measured and muscular wall thickness and external diameter were reported (19) .
Statistical analysis
Statistical analysis was carried out using the MedCalc statistical software version, 12.7.7.
Mann Whitney U test was applied for analyses of two groups that were not independent and not normally distributed. Median, minimum and maximum values were used. Log-rank tests were conducted to compare survival rates between groups. The statistical significance level was set at p<0.05.
RESULTS
Exercise capacity
Median exercise capacity significantly decreased with PAH application compared to control group (3.75 vs 6.43 min, respectively, p=0.009). This decrease was reversed by RAPA, but the difference between the PAH control and PAH-RAPA groups was not significant (3.75 vs.
6.85 min, respectively, p=0.51) (Figure 1 ).
Figure 1.
Exercise duration (min) in study groups. Although exercise duration was lower in PAH control group than control and PAH-RAPA groups, the difference was significant for only between control and PAH control groups (n=6-10).
Right ventricular systolic pressure
The right ventricular systolic pressure of PAH control group (median, 26 mmHg; range, 16- (Figures 4 and 5) . 
Survival
Eight rats (53.1%) in the PAH control group, and 6 (42.9%) in the PAH-RAPA group, and none in control group died during 35 days of follow-up ( Figure 6 ). The median lifetime duration was 32 and 35 days in PAH control and PAH-RAPA groups, respectively (log rank test, p= 0.006). The mortality rate differed significantly between the control and PAH control groups (p=0.006); however, there was no significant difference between the PAH control and PAH-RAPA groups (p=0.71) (Figure 7) . Figure 6 . Kaplan-Meier survival curves of the three groups. Mortality rates were 0% in control group, 53.1% in PAH control group and 42.9% in PAH-RAPA group. There was a significant difference between control and PAH control groups, but not between PAH control and PAH-RAPA groups (p=0.006 and p=0.71, respectively). (20) . Although PAH originates from abnormal pulmonary vasoconstriction, the disease is thought to proceed from pulmonary vascular remodeling. Eventually, these changes result in irreversible increases in pulmonary vascular resistance and right cardiac failure. Therefore, developing treatments that inhibit or reverse vascular remodeling is critical for the long-term management of PAH.
RAPA is an immunosuppressant used in transplant patients to prevent rejection (21) . It has recently also been used for cancer treatment, at restenosis of coronary artery stents (22, 23) .
Moreover, RAPA has been found to be effective against liver, kidney, pulmonary fibrogenesis (24) (25) (26) , likely by preventing proliferation and inhibiting extracellular matrix production (27) .
In our study, although, RAPA had no significant effect on exercise capacity, right ventricular hypertrophy, right ventricular systolic pressure, and 35-day mortality, it had positive effects of on pulmonary artery muscularization and 35-day life expectancy.
The preventative effect of RAPA on monocrotaline-induced PAH in rats was first reported by Nishimura. However, RAPA was unable to reverse PAH in this study (28) . Another study indicated that 2 mg/kg oral RAPA had a protective effect, which was linked to heme oxygenase-1 (29). PAH develops after 3 weeks in the monocrotaline-induced PAH model (35) . To analyze reversal effects of RAPA, the treatment was initiated on the 21st day and was of 14-day duration. We preferred not to use RAPA as a prevention strategy since PAH was diagnosed relatively late during the course of the disease. It has been reported that RAPA had a preventative effect on PAH when administered prior to its development. Several studies have reported that RAPA has reversal effects on PAH, and particularly vascular remodeling.
Controversial results regarding the reversal effects of RAPA may be related to the dose used.
More positive effects on PAH were noted when ≥3 mg/kg/day was administered. Besides, at human study of Seyfarth et al. detecting partial improvement at progressive PAH patients in spite of other treatments and observing protective effect more distinctively at animal studies made us think that RAPA may be more efficient treatment at early stage of PAH (34) .
The analysis of of exercise capacity in the current study is an important parameter because it denotes the functional significance of PAH and is used as an end-point in clinical studies.
Thus, the inclusion of this parameter contributes to the interpretation of the results of experimental studies from the clinical perspective.
CONCLUSION
In conclusion, positive effects of RAPA on pulmonary arterial muscularization were detected in our study. Despite the lack of statistical significance, improvements in exercise capacity, right ventricular systolic pressure, and right ventricular hypertrophy were detected. Use of RAPA derivatives has been approved for immune suppression after organ transplantation, for prevention of vessel restenosis after angioplasty, and for treatment of some malignancies.
Therefore, RAPA may have potential as a further option for treatment of PAH. 
